tiprankstipranks
Passage Bio Achieves Milestones in Gene Therapy Trials
Company Announcements

Passage Bio Achieves Milestones in Gene Therapy Trials

Passage Bio ( (PASG) ) has issued an update.

Don't Miss our Black Friday Offers:

Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This progress underscores Passage Bio’s commitment to advancing treatments for neurodegenerative diseases.

For an in-depth examination of PASG stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPassage Bio Shows Progress in Gene Therapy Trials
TheFlyPassage Bio reports Q3 EPS (31c), consensus (23c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App